AstraZeneca : Wainzua Recommended By CHMP For EU Approval In Hereditary Transthyretin Amyloidosis

(RTTNews) - AstraZeneca Plc. (AZN.L, AZN) and Ionis' Wainzua (eplontersen) has been recommended for approval by the Committee for Medicinal Products for Human Use (CHMP) in the European Union (EU) for the treatment of hereditary transthyretin-mediated amyloidosis in adult patient https://www.nasdaq.com/articles/astrazeneca-wainzua-recommended-chmp-eu-approval-hereditary-transthyretin-amyloidosis